Detailed price information for Vertex Inc Cl A (VERX-Q) from The Globe and Mail including charting and trades.

Vertex Pharmaceuticals (VRTX) is rated as a "Strong Buy" due to robust revenue growth and multiple expansion opportunities ...

Vertex, Inc. shares have plunged over 60% YTD, but valuation is now compelling after a post-earnings dip. Learn more about VERX stock here.

Vertex, Inc. (($VERX)) has held its Q3 earnings call. Read on for the main highlights of the call. Vertex, Inc. Earnings Call Reveals Mixed ...

Vertex, Inc. (NASDAQ: VERX) posted double-digit revenue growth in the third quarter of 2025 and announced its first-ever ...

KING OF PRUSSIA, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results ...

The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid ...

Vertex, Inc. (NASDAQ: VERX) ("Vertex" or the "Company"), a leading global provider of indirect tax solutions, today announced financial results ...

The stock, which is down more than 61% in 2025, sold off after reporting a Q3 EPS beat missing on revenue expectations.

Vertex Inc (VERX) reports robust cloud revenue growth and announces a $150 million share repurchase, despite facing customer ...

As the U.S. stock market navigates a mixed landscape with tech shares rebounding and the Dow Jones Industrial Average experiencing declines, investors are closely watching for opportunities amid ...